Humacyte
HUMA | NASDAQ
$0.50
-$0.02 (-4.12%)
At close: Oct 5, 2026, 4:00 PM ET
-4.12%
(1D)Rating
Key Statistics
Market Data
Market Cap $84M
1D Range
0.48 0.52
52W Range
0.48 2.55
Valuation (TTM)
PE -0.98
PB 2.69
EV/EBITDA -0.88
Valuation (NTM)
Forward PE N/A
Forward PEG -0.03
Price Target $2.00
Cash Flow
FCF Yield -116.1%
SBC Adj. FCF Yield -128.9%
SBC Impact -11.0%
Margins
Gross Margin -666.8%
Operating Margin -5240.8%
FCF Margin -4599.7%
Growth (CAGR)
Revenue 3Y | 5Y 309.0% |
2.4%
Dil EPS 3Y | 5Y 50.7% |
-1.7%
FCF 3Y | 5Y -8.2% |
-5.2%
Returns
ROA -70.0%
ROE -938.2%
ROIC -89.2%
Financial Health
Net Cash
$43.58M
Current Ratio 6.21
Interest Coverage -10.80
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array o...
Sector Healthcare
Industry Biotechnology
Employees 184
IPO Date Dec 1, 2020
Website www.humacyte.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
7
Consensus
Buy
Price Target
$2.00
Upside
+300.00%
Buy (5)
Hold (1)
Sell (0)
Add to Watchlist
Select watchlists to add or remove HUMA